Literature DB >> 27308593

Histone variant H2A.Z.2: A novel driver of melanoma progression.

Chiara Vardabasso1, Sandra B Hake2, Emily Bernstein1.   

Abstract

Histone variants are attracting attention in the field of cancer epigenetics. Our study has established a novel role for the uncharacterized histone variant H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 promotes cellular proliferation by recruiting BRD2 and E2F1 to E2F target genes and facilitating their transcription. High H2A.Z.2 expression correlates with poor survival in patients, and its depletion sensitizes cells to chemotherapy and targeted therapies.

Entities:  

Keywords:  BET; BRD2; E2F; H2A.Z; chromatin; histone variants; melanoma

Year:  2015        PMID： 27308593      PMCID： PMC4905390          DOI： 10.1080/23723556.2015.1073417

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

2.  BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Authors:  Miguel F Segura; Bárbara Fontanals-Cirera; Avital Gaziel-Sovran; María V Guijarro; Doug Hanniford; Guangtao Zhang; Pilar González-Gomez; Marta Morante; Luz Jubierre; Weijia Zhang; Farbod Darvishian; Michael Ohlmeyer; Iman Osman; Ming-Ming Zhou; Eva Hernando
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

Review 3.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 4.  Histone variants: emerging players in cancer biology.

Authors:  Chiara Vardabasso; Dan Hasson; Kajan Ratnakumar; Chi-Yeh Chung; Luis F Duarte; Emily Bernstein
Journal:  Cell Mol Life Sci       Date:  2013-05-08       Impact factor: 9.261

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

7.  Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.

Authors:  Chiara Vardabasso; Alexandre Gaspar-Maia; Dan Hasson; Sebastian Pünzeler; David Valle-Garcia; Tobias Straub; Eva C Keilhauer; Thomas Strub; Joanna Dong; Taniya Panda; Chi-Yeh Chung; Jonathan L Yao; Rajendra Singh; Miguel F Segura; Barbara Fontanals-Cirera; Amit Verma; Matthias Mann; Eva Hernando; Sandra B Hake; Emily Bernstein
Journal:  Mol Cell       Date:  2015-06-04       Impact factor: 17.970

8.  The histone variant macroH2A suppresses melanoma progression through regulation of CDK8.

Authors:  Avnish Kapoor; Matthew S Goldberg; Lara K Cumberland; Kajan Ratnakumar; Miguel F Segura; Patrick O Emanuel; Silvia Menendez; Chiara Vardabasso; Gary Leroy; Claudia I Vidal; David Polsky; Iman Osman; Benjamin A Garcia; Eva Hernando; Emily Bernstein
Journal:  Nature       Date:  2010-12-23       Impact factor: 49.962

9.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

10.  Decreased expression of the chromatin remodeler ATRX associates with melanoma progression.

Authors:  Zulekha A Qadeer; Sara Harcharik; David Valle-Garcia; Chen Chen; Miriam B Birge; Chiara Vardabasso; Luis F Duarte; Emily Bernstein
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551
  10 in total
  10 in total

Review 1.  Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer.

Authors:  David Corujo; Marcus Buschbeck
Journal:  Cancers (Basel)       Date:  2018-02-27       Impact factor: 6.639

2.  The histone variant H2A.Z in yeast is almost exclusively incorporated into the +1 nucleosome in the direction of transcription.

Authors:  Dia N Bagchi; Anna M Battenhouse; Daechan Park; Vishwanath R Iyer
Journal:  Nucleic Acids Res       Date:  2020-01-10       Impact factor: 16.971

3.  Targeted nanoparticle-mediated LHPP for melanoma treatment.

Authors:  Qianqian Zhang; Meimei Xiong; Jinlu Liu; Shuai Wang; Ting Du; Tianyi Kang; Yu Liu; Hao Cheng; Meijuan Huang; Maling Gou
Journal:  Int J Nanomedicine       Date:  2019-05-10

4.  Impact of CYLD on chromatin structure and histone methylation in malignant melanoma.

Authors:  Mandy Schott; Melanie Kappelmann-Fenzl; Stefan Fischer; Maite G Fernandez-Barrena; Antonio Pineda-Lucena; Matías A Ávila; Silke Kuphal; Anja-Katrin Bosserhoff
Journal:  Int J Mol Med       Date:  2022-03-16       Impact factor: 4.101

5.  Single Amino Acid Change Underlies Distinct Roles of H2A.Z Subtypes in Human Syndrome.

Authors:  Rachel S Greenberg; Hannah K Long; Tomek Swigut; Joanna Wysocka
Journal:  Cell       Date:  2019-09-05       Impact factor: 41.582

6.  H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.

Authors:  P A Ávila-López; G Guerrero; H N Nuñez-Martínez; C A Peralta-Alvarez; G Hernández-Montes; L G Álvarez-Hilario; R Herrera-Goepfert; J Albores-Saavedra; N Villegas-Sepúlveda; L Cedillo-Barrón; A E Montes-Gómez; M Vargas; M Schnoor; F Recillas-Targa; R Hernández-Rivas
Journal:  Oncogene       Date:  2021-02-24       Impact factor: 9.867

7.  HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs.

Authors:  Sanket G Shah; Tushar Mandloi; Pooja Kunte; Abhiram Natu; Mudasir Rashid; Divya Reddy; Nikhil Gadewal; Sanjay Gupta
Journal:  Epigenetics Chromatin       Date:  2020-08-03       Impact factor: 4.954

8.  Deciphering the Enigma of the Histone H2A.Z-1/H2A.Z-2 Isoforms: Novel Insights and Remaining Questions.

Authors:  Manjinder S Cheema; Katrina V Good; Bohyun Kim; Heddy Soufari; Connor O'Sullivan; Melissa E Freeman; Gilda Stefanelli; Ciro Rivera Casas; Kristine E Zengeler; Andrew J Kennedy; Jose Maria Eirin Lopez; Perry L Howard; Iva B Zovkic; Jeffrey Shabanowitz; Deanna D Dryhurst; Donald F Hunt; Cameron D Mackereth; Juan Ausió
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

Review 9.  Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression.

Authors:  Francesco Mannavola; Stella D'Oronzo; Mauro Cives; Luigia Stefania Stucci; Girolamo Ranieri; Franco Silvestris; Marco Tucci
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

10.  Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.

Authors:  Christopher J Terranova; Ming Tang; Mayinuer Maitituoheti; Ayush T Raman; Archit K Ghosh; Jonathan Schulz; Samir B Amin; Elias Orouji; Katarzyna Tomczak; Sharmistha Sarkar; Junna Oba; Caitlin Creasy; Chang-Jiun Wu; Samia Khan; Rossana Lazcano; Khalida Wani; Anand Singh; Praveen Barrodia; Dongyu Zhao; Kaifu Chen; Lauren E Haydu; Wei-Lien Wang; Alexander J Lazar; Scott E Woodman; Chantale Bernatchez; Kunal Rai
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.